Metacognitive Training Modulates Default-Mode Network Homogeneity During 8-Week Olanzapine Treatment in Patients With Schizophrenia.
default-mode network
metacognitive training
network homogeneity
olanzapine
schizophrenia
Journal
Frontiers in psychiatry
ISSN: 1664-0640
Titre abrégé: Front Psychiatry
Pays: Switzerland
ID NLM: 101545006
Informations de publication
Date de publication:
2020
2020
Historique:
received:
26
09
2019
accepted:
10
03
2020
entrez:
16
4
2020
pubmed:
16
4
2020
medline:
16
4
2020
Statut:
epublish
Résumé
Previous studies have revealed the efficacy of metacognitive training for schizophrenia. However, the underlying mechanisms of metacognitive training on brain function alterations, including the default-mode network (DMN), remain unknown. The present study explored treatment effects of metacognitive training on functional connectivity of the brain regions in the DMN. Forty-one patients with schizophrenia and 20 healthy controls were scanned using resting-state functional magnetic resonance imaging. Patients were randomly assigned to drug plus psychotherapy (DPP) and drug therapy (DT) groups. The DPP group received olanzapine and metacognitive training, and the DT group received only olanzapine for 8 weeks. Network homogeneity (NH) was applied to analyze the imaging data, and pattern classification techniques were applied to test whether abnormal NH deficits at baseline might be used to discriminate patients from healthy controls. Abnormal NH in predicting treatment response was also examined in each patient group. Compared with healthy controls, patients at baseline showed decreased NH in the bilateral ventral medial prefrontal cortex (MPFC), right posterior cingulate cortex (PCC)/precuneus, and bilateral precuneus and increased NH in the right cerebellum Crus II and bilateral superior MPFC. NH values in the right PCC/precuneus increased in the DPP group after 8 weeks of treatment, whereas no substantial difference in NH value was observed in the DT group. Support vector machine analyses showed that the accuracy, sensitivity, and specificity for distinguishing patients from healthy controls were more than 0.7 in the NH values of the right PCC/precuneus, bilateral ventral MPFC, bilateral superior MPFC, and bilateral precuneus regions. Support vector regression analyses showed that high NH levels at baseline in the bilateral superior MPFC could predict symptomatic improvement of positive and negative syndrome scale (PANSS) after 8 weeks of DPP treatment. No correlations were found between alterations in the NH values and changes in the PANSS scores/cognition parameters in the patients. This study provides evidence that metacognitive training is related to the modulation of DMN homogeneity in schizophrenia.
Sections du résumé
BACKGROUND
BACKGROUND
Previous studies have revealed the efficacy of metacognitive training for schizophrenia. However, the underlying mechanisms of metacognitive training on brain function alterations, including the default-mode network (DMN), remain unknown. The present study explored treatment effects of metacognitive training on functional connectivity of the brain regions in the DMN.
METHODS
METHODS
Forty-one patients with schizophrenia and 20 healthy controls were scanned using resting-state functional magnetic resonance imaging. Patients were randomly assigned to drug plus psychotherapy (DPP) and drug therapy (DT) groups. The DPP group received olanzapine and metacognitive training, and the DT group received only olanzapine for 8 weeks. Network homogeneity (NH) was applied to analyze the imaging data, and pattern classification techniques were applied to test whether abnormal NH deficits at baseline might be used to discriminate patients from healthy controls. Abnormal NH in predicting treatment response was also examined in each patient group.
RESULTS
RESULTS
Compared with healthy controls, patients at baseline showed decreased NH in the bilateral ventral medial prefrontal cortex (MPFC), right posterior cingulate cortex (PCC)/precuneus, and bilateral precuneus and increased NH in the right cerebellum Crus II and bilateral superior MPFC. NH values in the right PCC/precuneus increased in the DPP group after 8 weeks of treatment, whereas no substantial difference in NH value was observed in the DT group. Support vector machine analyses showed that the accuracy, sensitivity, and specificity for distinguishing patients from healthy controls were more than 0.7 in the NH values of the right PCC/precuneus, bilateral ventral MPFC, bilateral superior MPFC, and bilateral precuneus regions. Support vector regression analyses showed that high NH levels at baseline in the bilateral superior MPFC could predict symptomatic improvement of positive and negative syndrome scale (PANSS) after 8 weeks of DPP treatment. No correlations were found between alterations in the NH values and changes in the PANSS scores/cognition parameters in the patients.
CONCLUSION
CONCLUSIONS
This study provides evidence that metacognitive training is related to the modulation of DMN homogeneity in schizophrenia.
Identifiants
pubmed: 32292360
doi: 10.3389/fpsyt.2020.00234
pmc: PMC7118222
doi:
Types de publication
Journal Article
Langues
eng
Pagination
234Informations de copyright
Copyright © 2020 Shan, Liao, Ou, Ding, Liu, Chen, Zhao, Guo and He.
Références
Neurosci Biobehav Rev. 2012 Mar;36(3):1043-59
pubmed: 22230705
Schizophr Res. 2012 Jul;138(2-3):113-9
pubmed: 22480958
J Neurosci. 2013 Jan 30;33(5):1897-906
pubmed: 23365229
Brain. 2006 Mar;129(Pt 3):564-83
pubmed: 16399806
JAMA Psychiatry. 2014 Oct;71(10):1103-11
pubmed: 25103718
Psychiatr Clin North Am. 2007 Sep;30(3):511-33
pubmed: 17720034
J Affect Disord. 2016 Mar 15;193:81-8
pubmed: 26771948
Biol Psychiatry. 2011 Mar 1;69(5):415-23
pubmed: 21144498
Arch Gen Psychiatry. 2010 Aug;67(8):783-92
pubmed: 20679586
Front Psychiatry. 2018 Oct 30;9:532
pubmed: 30425661
Int J Psychophysiol. 2017 Feb;112:46-51
pubmed: 27989405
Brain Connect. 2014 Aug;4(6):395-403
pubmed: 24923194
Neuroinformatics. 2016 Jul;14(3):339-51
pubmed: 27075850
Neuroimage. 2011 Apr 15;55(4):1497-503
pubmed: 21134472
J Neurosci Methods. 2008 Mar 30;169(1):249-54
pubmed: 18190970
Behav Res Ther. 2011 Mar;49(3):151-7
pubmed: 21276962
Elife. 2016 Oct 25;5:
pubmed: 27776631
Behav Res Ther. 2015 Jan;64:38-42
pubmed: 25513971
Schizophr Bull. 2018 Feb 15;44(2):307-316
pubmed: 29106693
Schizophr Bull. 2013 Nov;39(6):1296-306
pubmed: 23172003
Neuroimage. 2015 Nov 15;122:272-80
pubmed: 26216278
Aust N Z J Psychiatry. 2017 Oct;51(10):1000-1009
pubmed: 28605934
Curr Opin Psychiatry. 2008 Mar;21(2):133-9
pubmed: 18332660
Cancer Genomics Proteomics. 2018 Jan-Feb;15(1):41-51
pubmed: 29275361
J Cogn Neurosci. 2012 Feb;24(2):475-81
pubmed: 21942762
Schizophr Bull. 2013 Nov;39(6):1288-95
pubmed: 23104865
Psychiatry Res Neuroimaging. 2017 Apr 30;262:8-14
pubmed: 28208070
Neuroimage. 2013 Apr 1;69:157-97
pubmed: 23194820
J Affect Disord. 2017 May;214:44-52
pubmed: 28266320
Schizophr Bull. 2019 Jan 1;45(1):27-36
pubmed: 30376124
Psychiatr Pol. 2016;50(4):787-803
pubmed: 27847929
J Neurosci. 2013 Oct 16;33(42):16657-65
pubmed: 24133268
Psychiatr Clin North Am. 2007 Sep;30(3):437-52
pubmed: 17720031
Psychiatry Res. 2014 Dec 30;224(3):218-24
pubmed: 25242670
Neuropsychopharmacology. 2018 Apr;43(5):1078-1087
pubmed: 28758644
Schizophr Res. 2014 Mar;153(1-3):54-9
pubmed: 24503175
Clin Psychol Psychother. 2016 Jul;23(4):329-39
pubmed: 25963712
Prog Neuropsychopharmacol Biol Psychiatry. 2014 Mar 3;49:16-20
pubmed: 24216538
Science. 2010 Sep 17;329(5998):1541-3
pubmed: 20847276
Neuropsychopharmacology. 2010 Mar;35(4):904-12
pubmed: 19956088
Schizophr Res. 2015 Aug;166(1-3):60-4
pubmed: 26116327
Schizophr Res. 2014 Aug;157(1-3):99-106
pubmed: 24972754
Eur Neuropsychopharmacol. 2017 Jan;27(1):48-58
pubmed: 27887859
Expert Rev Neurother. 2016;16(2):105-7
pubmed: 26694013
Science. 1988 Jun 3;240(4857):1285-93
pubmed: 3287615
Neural Netw. 2018 May;101:94-100
pubmed: 29494875
Curr Med Chem. 2013;20(3):428-37
pubmed: 23157635
Brain. 2014 Jan;137(Pt 1):12-32
pubmed: 23869106